Anlotinib in metastatic renal cell carcinoma (mRCC) with a previous anti-VEGFR TKI: Preliminary results from a multicenter, phase II trial.

被引：6
|
作者：
Zhou, Ai-Ping
Bai, Yuxian
Song, Van
Li, Hangzhong
Xie, Xiaodong
Ren, Xiu-Bao
Ye, Dingwei
Liu, Jiyan
Luo, Hong
Bai, Xianzhong
Qin, Shukui
Fu, Cheng
Wang, Jinwan
Ma, Jianhui
机构：
[1] Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China
[2] Harbin Med Univ Canc Hosp, Harbin, Heilongjiang, Peoples R China
[3] Peking Union Med Coll Hosp, Beijing, Peoples R China
[4] Gen Hosp Shenyang Mil Reg, Shenyang, Liaoning, Peoples R China
[5] Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China
[6] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[7] Sichuan Univ, West China Hosp, Dept Abdominal Canc, Ctr Canc, Chengdu, Sichuan, Peoples R China
[8] Chongqing Canc Hosp, Chongqing, Peoples R China
[9] Guangxi Med Univ, Affiliated Tumor Hosp, Nanning, Peoples R China
[10] Nanjing Bayi Hosp, Dept Med Oncol, Nanjing, Jiangsu, Peoples R China
[11] Liaoning Canc Hosp Inst, Shenyang, Liaoning, Peoples R China
[12] Chinese Acad Med Sci, Canc Inst & Hosp, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e16082
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16082
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Anlotinib versus sunitinib as first line treatment for metastatic renal cell carcinoma (mRCC): Preliminary results from a randomized phase II clinical trial
    Zhou, Ai-Ping
    Ma, Jianhui
    Bai, Yuxian
    Song, Yan
    Li, Hangzhong
    Xie, Xiaodong
    Ren, Xiu-Bao
    Ye, Dingwei
    Liu, Jiyan
    Luo, Hong
    Bai, Xianzhong
    Qin, Shukui
    Fu, Cheng
    Wang, Jinwan
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial.
    Motzer, Robert J.
    Rini, Brian I.
    McDermott, David F.
    Redman, Bruce G.
    Kuzel, Timothy
    Harrison, Michael Roger
    Vaishampayan, Ulka N.
    Drabkin, Harry A.
    George, Saby
    Logan, Theodore F.
    Margolin, Kim Allyson
    Plimack, Elizabeth R.
    Waxman, Ian
    Lambert, Alexandre
    Hammers, Hans J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] Prospective phase II study of sunitinib rechallenge in metastatic renal cell carcinoma (mRCC): A GION trial.
    Porta, Camillo
    Ferrari, Vittorio D.
    Zucali, Paolo Andrea
    Fornarini, Giuseppe
    Bernardo, Antonio
    Falconeri, Andrea
    Ferrari, Alessandra
    Santarossa, Sandra
    Pappagallo, Giovanni L.
    Bearz, Alessandra
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] A PHASE I/II STUDY OF TKI258 (DOVITINIB), A FGFR AND VEGFR INHIBITOR, IN PATIENTS (PTS) WITH ADVANCED OR METASTATIC RENAL CELL CANCER (MRCC): PRELIMINARY PHASE II RESULTS
    Angevin, E.
    Gruenwald, V.
    Lin, C.
    Ravaud, A.
    Lopez, J. A.
    Kruit, W.
    Tykodi, S.
    Gschwend, J.
    Harzstark, A.
    Escudier, B.
    ANNALS OF ONCOLOGY, 2010, 21 : 166 - 166
  • [5] Association of statins and nivolumab activity in patients with metastatic renal cell carcinoma (mRCC): Results from the phase II nivoren-GETUG AFU 26 trial.
    Colomba, Emeline
    Flippot, Ronan
    Dalban, Cecile
    Negrier, Sylvie
    Chevreau, Christine
    Gravis, Gwenaelle
    Oudard, Stephane
    Laguerre, Brigitte
    Barthelemy, Philippe
    Goupil, Marine Gross
    Geoffrois, Lionnel
    Rolland, Frederic
    Thiery-Vuillemin, Antoine
    Joly, Florence
    Ladoire, Sylvain
    Tantot, Florence
    Escudier, Bernard
    Albiges, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [6] Angiogenesis related blood biomarkers of response to checkpoint inhibitors (IO) and VEGFR-TKI in metastatic renal cell carcinoma (mRCC): Results from the BIONIKK prospective trial
    Mauge, L.
    Galy-Fauroux, I.
    Elaidi, R-T.
    Ben Dhia, L.
    Bertil, S.
    Bennamoun, M.
    Chevreau, C. M.
    Borchiellini, D.
    Pannier, D.
    Maillet, D.
    Gross-Goupil, M.
    Tournigand, C.
    Laguerre, B.
    Barthelemy, P.
    Joly, F.
    Gravis, G.
    Zucman-Rossi, J.
    Oudard, S. M.
    Vano, Y.
    Helley, D.
    ANNALS OF ONCOLOGY, 2021, 32 : S704 - S704
  • [7] Phase II trial of motexafin gadolinium (MGd) for treatment of metastatic renal cell carcinoma (MRCC).
    Jac, J
    Hernandez, J
    Phan, SC
    Amato, RJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 433S - 433S
  • [8] Phase I/II trial of pembrolizumab and cabozantinib in the treatment of metastatic renal cell carcinoma (mRCC).
    Kessler, Elizabeth R.
    Hu, Junxiao
    Srivastava, Geetika
    Kemme, Douglas Jerome
    Iruku, Praveena
    Rana, Vishal
    Schuster, Steven Robert
    Amirault, Mali
    Callihan, Eryn
    Flaig, Thomas W.
    Lam, Elaine Tat
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial.
    Rini, B. I.
    Escudier, B.
    Tomczak, P.
    Kaprin, A.
    Hutson, T. E.
    Szczylik, C.
    Tarazi, J. C.
    Rosbrook, B.
    Kim, S.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] Anlotinib in chemotherapy-refractory metastatic esophageal squamous cell carcinoma (ESCC): A randomized, double-blind, multicenter phase II trial.
    Huang, Jing
    Xiao, Juxiang
    Fang, Wentao
    Lu, Ping
    Fan, Qingxia
    Shu, Yongqian
    Feng, Ji Feng
    Zhang, Shu
    Ba, Yi
    Liu, Ying
    Bai, Chunmei
    Bai, Yu-Xian
    Tang, Yong
    Song, Yan
    He, Jie
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
12345